Highlights Celltrion, Inc.

Stocks

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 10/07/2026			5-day change	1st Jan Change
1,75,200.00 ^KRW	+1.21%		-4.58%	+1.64%

07/07	Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA	MT
03/07	South Korean Shares Jump on Bargain-Hunting, Chip Stock Gains	MT

Highlights

03/07	Celltrion's Sales Jump 35% in Q2; Shares Rise 4%	MT
30/06	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 21, 2026.	CI
26/06	Celltrion, Inc.'s Equity Buyback announced on May 21, 2026, has closed with 586,927 shares, representing 0.26% for KRW 99,872.81 million.	CI
21/05	Celltrion, Inc. authorizes a Buyback Plan.	CI
21/05	Celltrion, Inc. announces an Equity Buyback for 557,414 shares.	CI
21/05	Celltrion Inc to acquire 100 billion won worth of own shares	RE
15/05	Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
08/05	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 22, 2026.	CI
06/05	Celltrion's Net Attributable Income Jumps 219% in Q1	MT
06/05	Celltrion to Retire KRW100 Billion Worth of Treasury Shares	MT
06/05	Celltrion Q1 operating profit 322 billion won, up 115% Y/Y	RE
06/05	Celltrion to cancel 100 billion won treasury shares	RE
06/05	Celltrion, Inc.'s Equity Buyback announced on April 22, 2026, has expired with 488,977 shares, representing 0.22% for KRW 99,999.87 million.	CI
30/04	Celltrion, Inc. agreed to acquire Gifrer Barbezat SAS.	CI
22/04	Celltrion, Inc. authorizes a Buyback Plan.	CI
22/04	Celltrion, Inc. announces an Equity Buyback for 492,611 shares.	CI
22/04	Celltrion to buy 100 billion won of own shares	RE
23/03	Worker Dies After Fatal Fall at Celltrion's Incheon Plant; Shares Decline 6%	MT
17/03	Celltrion Secures Pharmaceutical Manufacturing Contract; Shares Rise 3%	MT
16/03	Celltrion Inc Announces U S Availability Of AVTOZMA® (tocilizumab-anoh) Subcutaneous (SC) Formulation	CI
16/03	Celltrion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
09/03	Celltrion Expands Treasury Share Cancellation	MT
14/01	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
02/01	Celltrion Shares Rally on U.S. Contract, Earnings Outlook	DJ
18/12	Celltrion, Inc. Receives Positive CHMP Opinion for SteQeyma (Uustekinumab Biosimilar) Autoinjector	CI